BRYNELSEN CHARLES

Director Bryn Elsen bought 1,000,000 shares of COCH at $0.40; stock now $0.69 but holder of 2,000.0% prior-holding increase amid cluster activity

Charles Bryn Elsen (Director) purchased 1,000,000 shares at $0.40 on 2026-02-12, raising his holdings from 50,000 to 1,050,000 shares. The buy occurred at $0.39–$1.72 52-week range lows and represents a 2000.0% increase relative to his pre-transaction holdings. However, his cross-ticker track record shows 3 prior buys with an average 90-day return of -28.3% and a 0.00% win rate, while his same-ticker history at COCH shows three consecutive buys (2025-05-22, 2025-05-23, 2025-05-27), each generating negative 90-day returns (-24.6%, -28.2%, -32.0% respectively). Envoy Medical reported revenue of $42,000.00 in the latest quarter, net income of $-6,482,000.00, annual revenue decline of -28.8%, and a market cap of $19,862,692.59 while unprofitable. The transaction occurred alongside 5 other insider buys within 14 days, forming a cluster pattern, though the fundamental weakness and insider timing history suggest caution.

Director Charles Brynelsen purchased 50,000 shares for $82,402.70 across 3 transactions at Envoy Medical (COCH), blended avg $1.65.

Charles Brynelsen, a director at Envoy Medical, acquired a 50,000 share position through 3 separate purchases between May 22–27, 2025, at prices ranging from $1.64 to $1.68 per share. This represents a new position (0 shares pre-transaction). The company faces significant headwinds: annual revenue declined 28.8% year-over-year, the latest quarterly revenue was $46,000.00, net income is negative at $-5.0M, and market cap is $33.3M. The stock is currently trading at $1.56, down 58.1% from its 52-week high of $3.72, although it has risen 5.4% over the past 30 days and 13.9% over 90 days. The director's entry at $1.65 occurred in the context of steep valuation declines and operational deterioration, adding to the observed recent price rebound but without evidence of a fundamental inflection.